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T riple negative breast cancer (TNBC) is associated with a poor prognosis compared to other types of breast cancer. The classification of 'triple negative' is not one homogenous tumor type, but rather is made up of multiple molecularly and biologically diverse tumor subtypes. At present, no approved targeted therapy exists and the standard remains cytotoxic chemotherapy. The identification 
of TNBC subtypes has provided a basis for identifying possible targeted therapeutic options. In addition, the recognition that some TNBCs 
share characteristics similar to tumors arising in patients with germline BRCA mutations has led to consideration of DNA damaging agents 
as a potential treatment option. Multiple investigational approaches are also underway, including immune checkpoint inhibition, poly 
(ADP-ribose) polymerase inhibition, and androgen receptor blockage. The limited options available for systemic treatment of TNBC will hopefully 
expand as more is learned about the complex biology and molecular targets of this group of breast cancers. This review will discuss the biology 
of TNBC, current treatment options, and promising experimental strategies.
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Triple negative breast cancer (TNBC) is defined by a lack of expression of estrogen receptor (ER) 
and progesterone receptor (PR), and a lack of overexpression or amplification of human epidermal 
growth factor 2 (HER2) on tumor cells. TNBC accounts for approximately 15–20% of all breast cancers 
diagnosed in the United States.1 It is more common in African American women, younger women, 
and those with a germline BRCA1 mutation. Due to lack of ER, PR, and HER2 and the significant 
heterogeneity among TNBC, no approved targeted therapies exist and standard treatment remains 
cytotoxic chemotherapy. While response rates to chemotherapy in early stage disease are high, 
patients remain at high risk for relapse and prognosis remains inferior to other types of breast cancer.
Subtyping and molecular characteristics
In a seminal paper by Perou et al., gene expression profiling was used to categorize breast cancers 
into five molecular subtypes. The basal-like type is characterized by lack of ER, PR, and HER2 
expression, expression of cytokeratins and EGFR, and a clinically more aggressive phenotype.2 This 
subtype overlaps with TNBC but the terms are not synonymous; in fact, about one fourth of TNBCs 
are not basal-like by gene expression, and some non-TNBCs are basal-like by molecular profiling 
(see Figure 1).3,4 As more is discovered about the biology of TNBC, it has become clear that this 
category of breast cancer is not one homogeneous tumor type, but rather is made up of a group of 
molecularly diverse tumor subtypes. These subtypes have varying gene expression profiles, clinical 
characteristics, and responses to treatment. In an effort to translate the heterogeneity of TNBC into 
rational clinical design, Lehmann and colleagues further characterized TNBC into six distinct subtypes 
based on molecular profiles, each with unique drivers and clinical phenotypes. These subtypes 
include basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal 
stem-like (MSL), and luminal androgen receptor(LAR).5 Each exhibited different sensitivities to 
therapeutic agents, both in cell line models and in some retrospective clinical trials. For example, the BL1 
subtype responds preferentially to platinum agents and responds significantly better to neoadjuvant 
chemotherapy than the BL2 subtype. The mesenchymal and luminal subtypes have greater sensitivity 
to phosphatidylinositol 3- kinase (PI3K) pathway inhibitors, while the LAR subtype is more sensitive to 
androgen receptor antagonists, with a relative insensitivity to standard chemotherapy.5–9
This heterogeneity and the lack of targetable oncogenic mutations have made the development of 
novel strategies for TNBC difficult. Common genomic alterations in TNBC result in dysregulated cell 
cycle progression and resistance to apoptosis, including the loss of TP53, RB1, BRCA1, and PTEN, as 
well as gain of function alterations in the cyclins/cyclin-dependent kinases (CCNE1, CCND1, CDK4, 
CDK6) and the PI3K pathway, including PIK3CA mutations.10–12 The most common of these alterations 
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is a mutation or loss of TP53, which is present in 68% of TNBCs and 80% of 
basal-like breast cancers in The Cancer Genome Atlas (TCGA), but is yet to 
have a targeted therapeutic agent.10
Further understanding of the biology of TNBC has come from the discovery 
that some sporadic tumors share similar characteristics with those tumors 
that have a germline mutation in the DNA repair gene BRCA1, which plays 
a role in DNA double-strand break repair by homologous recombination. 
This has led to the term ‘BRCAness,’ referring to genotypes of TNBC that 
are BRCA proficient but exhibit a clinical and biologic phenotype similar 
to those with BRCA deficiencies. There are likely alternative mechanisms 
leading to defects in homologous recombination in TNBCs without 
germline BRCA1/2 mutations, including promotor methylation, somatic 
BRCA mutations, and altered expression of other genes, such as TP53, 
PALB2, ATM, and HORMAD1. This phenotype has important implications, as 
TNBCs that harbor defects in homologous recombination have therapeutic 
sensitivities similar to those with BRCA mutations.13
Current management of early stage disease
Given the lack of approved targeted agents, the mainstay of treatment for 
TNBC is not unique and continues to be cytotoxic chemotherapy. All eligible 
patients with tumors over 0.5 cm in size should receive treatment with 
chemotherapy in either the neoadjuvant or adjuvant setting. There is no 
evidence favoring the use of neoadjuvant over adjuvant therapy in terms 
of outcome, but the neoadjuvant setting offers the advantage of having 
measurable disease to assess response to therapy, providing prognostic 
information. In addition, neoadjuvant therapy is the preferred approach for 
those patients who are not operable at diagnosis or who are not candidates 
for breast conserving therapy due to tumor size or location. 
Pathologic complete response
TNBC has a higher response rate to neoadjuvant chemotherapy compared 
to breast cancers that are ER positive and a similar response rate to 
those that are HER2 positive. Those with TNBC who achieve a pathologic 
complete response (pCR) have improved outcomes compared to those 
who have residual disease.14,15 In a pooled analysis by Cortazar et al., there 
was an improvement in event free survival (EFS) (HR 0.24) and OS (HR 0.16) 
in patients with TNBC who achieved a pCR. However, pCR could not be 
validated as a surrogate endpoint for survival on a trial level analysis.15 In 
the neoadjuvant CALGB 40603 study, a pCR in the breast and axilla was 
associated with a 70% decrease in the risk of recurrence and an 80% 
decrease in the risk of death at three years.16 However, despite significantly 
more patients with TNBC achieving a pCR than those with luminal breast 
cancers, those with TNBC have a higher risk of recurrence. This paradox is 
likely due to the poorer prognosis of patients with residual disease. Residual 
disease in patients with TNBC confers a worse prognosis than residual 
disease in those with non-TNBC, with a significantly shorter recurrence free 
survival, decreased overall survival, and increased likelihood of developing 
visceral metastases.17,18
Choice of regimen
Similar to treatment of hormone positive or HER2 positive breast cancer, 
the preferred chemotherapy regimens in either the neoadjuvant or 
adjuvant setting contain an anthracycline and/or a taxane. The optimal 
regimen is not well defined and the choice of therapy ultimately depends 
on patient characteristics and preferences. There has been question of 
whether anthracyclines could be withheld in patients with HER2 negative 
breast cancer in the curative setting in order to avoid additional toxicity. 
A large pooled analysis by Gennari et al. in 2008 showed no added benefit in 
terms of disease-free or overall survival for the addition of an anthracycline 
to adjuvant chemotherapy.19 In addition, in a phase III trial by Jones et al. 
in 2006 comparing adjuvant doxorubicin plus cyclophosphamide (AC) 
to docetaxel plus cyclophosphamide (TC) in all types of breast cancer, 
disease-free survival (DFS) favored the TC arm and established this as an 
effective non-anthracycline choice.20 However, results recently presented at 
the 2016 American Society of Clinical Oncology (ASCO) annual meeting of 
the pooled ‘ABC trials’ (USOR 06-090, NSABP B-46I/USOR 07132, and NSABP 
B-49) settled this question. The trials sought to evaluate whether TC was 
non-inferior to AC with a taxane. Results of the pooled analysis found that 
TC was not as effective as the regimens containing both an anthracycline 
and a taxane with a HR of 1.23 (p=0.04), or a 23% reduction in recurrence, 
favoring anthracyclines. The benefit was greatest in the HER2 negative, ER 
negative patients, with a HR of 1.42.21 While increased risk of heart failure 
and secondary leukemia should be discussed with patients, anthracyclines 
should not be withheld unless clinically necessary, and TC should not be 
considered an equivalent regimen in patients with TNBC.
Role of additional agents
Improving upon the anthracycline and taxane backbone has proven to 
be difficult. Despite initial promise for antiangiogenic therapy in breast 
cancer, phase III trials of the addition of the vascular endothelial growth 
factor (VEGF) inhibitor bevacizumab to adjuvant chemotherapy in TNBC 
failed to show improvement in disease-free or overall survival.22 In 
addition, the role of the addition of the antimetabolites capecitabine 
and gemcitabine remains unclear, with mixed results. Recently reported 
long-term outcomes from the FinXX trial of adjuvant capecitabine added 
to docetaxel, epirubicin, and cyclophosphamide showed no significant 
improvements in recurrence-free survival (RFS) or OS. While the subgroup 
analysis did how improvement for TNBC (RFS HR 0.54, OS HR 0.55), these 
results should be interpreted with caution given the small sample size. 
The US Oncology group trial 01062 also failed to show a DFS benefit when 
capecitabine was added to an anthracycline and taxane backbone.23 
Furthermore, the addition of gemcitabine also did not improve outcomes 
in the NSABP B-38 study when added to adjuvant chemotherapy.24 In the 
Japanese CREATE-X trial, adjuvant capecitabine alone did improve DFS 
and OS in patients with HER2 negative disease who did not achieve a 
pCR after neoadjuvant anthracycline and taxane therapy, with the 
Figure 1: Venn diagram depicting the relationship between 
the triple negative immunophenotype and the basal-like 
molecular subtype
ER = estrogen receptor; HER2 = human epidermal growth factor 2; PR = progesterone 
receptor.
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most impressive benefit being for patients with TNBC.25 The results are 
hypothesis-generating, and while capecitabine may be beneficial for a 
highly selective patient population, its role in early TNBC requires further 
study before routine clinical use.
Role of platinum agents
Similar to TNBCs arising in patients with germline BRCA mutations, many 
sporadic TNBCs also harbor defects in aspects of DNA repair, such as 
homologous recombination.26 Preclinical work has shown that BRCA1 
deficiency predisposes tumors to be sensitive to platinum chemotherapy 
agents because the ability to repair DNA crosslinks created by platinum 
agents requires homologous recombination. Several neoadjuvant clinical 
trials have shown sensitivity to single agent platinum therapy,27,28 as well 
as increased pathologic complete response rates following neoadjuvant 
chemotherapy containing platinum agents.26,29 The largest of these is the 
CALGB 40603 study, in which 443 patients with stage II-III TNBC receiving 
a backbone of weekly paclitaxel for 12 weeks followed by dose-dense 
AC were randomized to also receive carboplatin, bevacizumab, or the 
combination of carboplatin and bevacizumab in a 2 x 2 design. The addition 
of carboplatin resulted in an improved pCR rate of 54%, compared to 41% 
in the control group (OR 1.7). In the German GeparSixto study, 315 TNBC 
patients received paclitaxel with liposomal doxorubicin and bevacizumab 
with or without carboplatin. The addition of carboplatin resulted in an 
improvement in pCR from 37% to 53% (OR 1.94). The question of whether 
the increased pCR rates translate to an improvement in outcome 
remains unclear. In the GeparSixto study, the addition of carboplatin 
improved three-year DFS from 76.1% to 85.8% (HR 0.56); however, in the 
CALGB 40603 study, the improvement in EFS was less impressive and 
not significant (71.6% to 76.5%, HR 0.84).16,30 This difference may be due 
to the fact that neither trial was powered for these survival endpoints. 
The GeparSixto study contained more node negative patients, used a non-
standard regimen, and used weekly carboplatin, rather than the every-
three-week dosing used in CALGB 40603. In addition, it is important to 
note that toxicity is not trivial for the addition of carboplatin. Patients in 
the carboplatin arm of CALGB 40603 were more likely to have dose delays, 
miss treatments, or stop treatment early.
The ultimate benefit, most appropriate regimen, and optimal dosing schedule 
for integration of platinum remains unknown, and we will await the results 
of ongoing clinical trials. The NRG-BR003 trial (NCT02488967) will evaluate 
the addition of carboplatin every three weeks to adjuvant AC followed by 
paclitaxel. ECOG-ACRIN 1131 (NCT02445391) will randomize patients with 
residual basal-like disease following neoadjuvant chemotherapy to either a 
platinum agent or capecitabine. 
Current management of metastatic disease
The risk for distant recurrence of TNBC peaks at approximately three years, 
then rapidly declines.31 TNBC commonly recurs with visceral metastases 
in the lung and liver, with about 15% of TNBC patients developing brain 
metastases.1 There is no current standard for the management of TNBC in 
the metastatic setting, and treatment continues to be a choice between 
cytotoxic chemotherapies depending on the specific patient. Given that the 
goal is palliation, individualized discussion with patients and consideration 
of the side effects or dosing schedules that will affect quality of life is 
essential. Few studies have focused on the TNBC subset alone in the 
metastatic setting, and the majority of data discussed here are not specific 
to triple negative disease.
Notably, there is no improvement in survival outcomes when chemotherapy 
agents are used in combination, compared to sequential use of single 
agents.32 However, for the highly selective patient who is deemed clinically 
to need a rapid tumor response to therapy in a short amount of time, 
combination therapy is reasonable. For patients who relapse later after 
primary therapy or present with de novo metastatic disease, it is reasonable 
to initiate therapy with a taxane. While docetaxel was shown in a randomized 
trial to have significant improvement in survival compared to every-
three-week paclitaxel in the metastatic setting, docetaxel is associated 
with higher rates of toxicity, including myelosuppression.33 In addition, the 
preferred dosing of paclitaxel with weekly administration has never been 
compared to docetaxel in the metastatic setting. Docetaxel undergoes 
hepatic metabolism and therefore may not be a drug of choice for patients 
with significant liver tumor burden. Albumin bound nab-paclitaxel has the 
advantage of not requiring steroid pre-medication due to a decreased 
risk of allergic reaction with this formulation. However, in the randomized 
study CALGB 40502, there was no difference in outcome between weekly 
paclitaxel compared to weekly nab-paclitaxel used in the firstline setting, 
with more neuropathy and myelosuppression seen in the nab-paclitaxel 
arm.34 This study also included an arm with the non-taxane tubulin 
polymerizer ixabepilone, which proved inferior to paclitaxel. Most patients in 
this study also received bevacizumab; however, similar to outcomes in early 
breast cancer, the addition of bevacizumab to a taxane in the metastatic 
setting increases response rates and PFS, with no benefit in OS.35
Other choices include the anthracyclines, with the caveat that maximum 
lifetime anthracycline exposure is a limiting factor in patients with prior 
exposure in the neoadjuvant or adjuvant setting. Other active agents 
include the microtubule inhibitor eribulin, the antimetabolites gemcitabine 
and capecitabine, and the vinca alkaloid vinorelbine. Eribulin was compared 
to physicians’ choice in patients with pretreated metastatic breast cancer, 
20% of whom had TNBC, and resulted in significant improvement in OS (13.1 
versus 10.6 months, HR 0.81), with neutropenia and peripheral neuropathy 
being significant side effects.36 This was the first study to show a benefit in 
pretreated patients using OS as the primary endpoint. A systematic review of 
capecitabine single agent therapy in patients with metastatic breast cancer 
and prior exposure to taxanes and anthracyclines showed a response 
rate of 18% and OS of 13.5 months.37 Capecitabine combinations have 
also been evaluated in the metastatic setting, with mixed results. Despite 
improvements in response rates and OS seen with some combinations, 
including docetaxel with capecitabine, the increase in toxicity has hindered 
adoption into routine clinical practice.38 A randomized study of eribulin 
versus capecitabine showed no statistical superiority of eribulin over 
capecitabine in PFS or OS;39 however, a recently published exploratory, pre-
specified subgroup analysis did show a greater survival advantage with 
eribulin for patients with TNBC.40 Gemcitabine and vinorelbine also have 
activity as single agents in first line and pretreated metastatic breast cancer, 
with response rates of approximately 20–50%, and both are commonly 
used due to favorable side effect profiles.41–44 Notably, gemcitabine has 
proven inferior to eribulin in the firstline metastatic setting.45 
Similar to early-stage disease, the role of platinum agents in metastatic 
TNBC is promising but remains unclear. In the TNT trial of first line docetaxel 
versus carboplatin for metastatic TNBC, presented at the 2014 San Antonio 
Breast Cancer Symposium, there was no difference seen in response rates 
or survival.46 Among the BRCA1/2 positive patients, there was a 34.7% 
increase in response rates and significant improvement in PFS, but this 
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subgroup contained only 43 patients. Overall, the majority of studies in the 
metastatic setting are underpowered and contain only small subsets of 
TNBC patients.
Novel and targeted agents
The transcriptional heterogeneity and lack of high-frequency mutations in 
TNBC add to the difficulty in creating targeted therapeutics. Interestingly, 
this can change under the influence of chemotherapy, which can increase 
the frequency of PTEN, PI3K, mTOR, and amplify JAK2, CDK6, CCND1, CCND2 
and CCND3.12 For this subset of patients, there may be future prospects in 
targeted treatments. 
Immune checkpoint inhibitors
The advent of immunotherapy and further understanding of the host 
immune system in highly proliferative cancers has opened opportunities 
in the study of TNBC. There is increasing evidence surrounding the role 
of tumor infiltrating lymphocytes (TILs) in TNBC. TILs have been associated 
with increased pCR rates and improved DFS and OS in TNBC. In the adjuvant 
BIG 02–98 trial, a 10% increase in intratumoral or stromal lymphocytic 
infiltrate was associated with a 17% or 25% reduced risk of relapse, and 
a 27% or 17% reduced risk of death in TNBC, respectively.47 This and other 
outcome reports are suggestive of significant involvement of the immune 
system.48 Further research has found programmed cell death protein 
1 ligand (PD-L1), which plays a role in inactivation of the host immune 
system, to be amplified in basal-like tumors and significantly correlated 
with the presence of TILs,49 providing a rationale for targeting the PD1/
PD-L1 axis in TNBC. Two immune checkpoint inhibitors have been studied 
extensively in TNBC: the anti-PD-1 antibody pembrolizumab (MK-3475), 
and the anti-PD-L1 antibody atezolizumab (MPDL3280A). While there has 
been much excitement in the area of immunotherapy for TNBC, there is 
a relative paucity of data. The resulted clinic trials are detailed in Table 1, 
which have shown safety and clinical activity of single agents as well as in 
the combination of atezolizumab with nab-paclitaxel.50–53 While the PFS is 
short across these studies, patients who respond appear to have durable 
and ongoing responses. These compounds are being evaluated in larger 
trials in the neoadjuvant and metastatic setting. Additionally, studies of 
combinations of immunotherapy with chemotherapy are ongoing, including 
the phase III Impassion130 study of nab-paclitaxel plus atezolizumab in the 
first line metastatic setting (NCT02425891).
Antibody drug conjugates
Antibody drug conjugates (ADCs), which combine monoclonal antibodies 
with effector molecules and allow the cancer cell to internalize the 
antibody, are being studied for improved drug delivery and toxicity 
profile. One such ADC, glembatumumab vedotin (CDX-011 or CR011-
vcMMAE), is a combination of a gpNMB-specific monoclonal antibody and 
cytotoxin monomethyl auristatin E (MMAE). The glycoprotein gpNMB is 
overexpressed in TNBC and associated with increased risk of recurrence 
and metastases, while MMAE serves as a potent microtubule inhibitor.54,55 
This ADC has been found to have enhanced activity against TNBC in early 
trials and is undergoing further investigation in larger trials such as EMERGE 
(NCT01156753) and METRIC (NCT01997333). Most recently, the ADC 
sacituzumab govitecan (IMMU-132), has been making headlines. This ADC is 
a combination of a moderately toxic drug SN-38, which is a topoisomerase 
I inhibitor that is the insoluble potent metabolite of irinotecan, and an anti-
Trop-2 monoclonal antibody targeting a glycoprotein found in TNBC. In a 
phase II study, the objective response rate was 31.5% with manageable 
toxicity, and the drug has been granted Breakthrough Therapy Designation 
and Fast Track Designation by the FDA in patients with TNBC following at 
least two previous treatments for metastatic disease.56 Phase III research is 
pending (NCT02574455).
Poly-ADP polymerase inhibitors
Tumors arising in patients with BRCA1/2 mutations or those exhibiting a 
‘BRCAness’ phenotype are characterized by deficiencies in homologous 
recombination DNA repair mechanisms, which has led to the evaluation 
of poly-ADP polymerase inhibitors (PARPi) in TNBC. PARP activation 
drives the synthesis of machinery involved in alternative mechanisms of 
DNA damage repair aside from homologous recombination. The rationale 
is that homologous recombination deficient cells will be reliant on PARP 
activation for DNA damage repair, and therefore particular sensitive 
to PARPi. Initial phase I and II data for BRCA- associated breast and 
ovarian cancers has shown promising results for PARPi as monotherapy, 
including veliparaib, olaparib, niraparib, talazoparib, and rucaparib, 
with response rates ranging from 0 – 50%. There are also phase I and 
II studies of PARPi in combination with other agents in the metastatic 
setting showing efficacy in terms of response rates and clinical benefit. 
Table 2 highlights trial results for those multicenter trials that provide 
results for the BRCA mutated breast cancer population specifically. 
Trials in the non-mutated BRCA population are ongoing, hoping to 
identify a population with similar DNA repair defects. Ongoing phase 
III trials in the metastatic setting are evaluating PARPi monotherapy 
versus other single agents in patients with BRCA1/2 mutations (BRAVO 
NCT01905592, EMBRACA NCT01945775, and OlympiAD NCT02000622), 
and the study NCT02163694 is evaluating veliparib versus placebo in 
combination with carboplatin and paclitaxel. In the neoadjuvant setting, 
Table 1: Results of clinical trials using immune checkpoint inhibitors in triple negative breast cancer
Drug Phase Population Number Results in TNBC
Pembrolizumab50 Ib Solid tumors, including heavily pre-treated 
metastatic TNBC, PDL1 positive
27 patients with TNBC evaluable 
for efficacy
ORR 18.5% (1 CR, 4 PR), median duration of response not 
reached (longest 47 weeks and ongoing)
Atezolizumab51 Ia Solid tumors, including heavily pre-treated 
metastatic TNBC
27 patients with TNBC evaluable 
for efficacy
ORR 19% (2 CR, 2 PR), median duration of response not 
reached (longest 84 weeks and ongoing)
Avelumab52 I Locally advanced or metastatic breast 
cancer
58 patients with TNBC ORR for all patients 4.8% (5 of 8 responses were in TNBC)
Atezolizumab plus 
nab-paclitaxel53
I Metastatic TNBC 32 patients evaluable for efficacy ORR 46% in 1st line, 22% in 2nd line, 40% in the 3rd line 
setting (0 CR, 4 PR)
CR = complete response; ORR = overall response rate; PR = partial response; TNBC = triple negative breast cancer.
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velparib in combination with carboplatin was recently found to have a 
pCR of 51% in patients with TNBC in the adaptive randomization trial 
I-SPY2, supporting further phase III study.57 The OlympiA trial of one 
year of olaparib in the adjuvant setting for patients with germline BRCA 
mutations is also ongoing (NCT02032823).
Androgen receptor blockade
The luminal androgen receptor (LAR) subtype of TNBC is characterized 
by chemoresistance, yet a lower risk of disease recurrence.67 It was 
hypothesized the AR inhibition would result in antitumor activity in this 
subtype of TNBC, a principle that was proved in the TBCRC001 phase II 
trial of bicalutamide in which 26 patients with AR positive, ER negative 
metastatic breast cancer had a 19% clinical benefit rate.8 A larger phase 
II trial of enzalutamide enrolling 118 patients with metastatic, AR positive 
TNBC showed a clinical benefit rate of 35% in evaluable patients. This 
study also showed that responses were better in those tumors with an 
androgen gene signature.68 These data support identifying patients with 
androgen receptor positivity and encourage additional clinical trials.
Additional therapeutic targets
An additional pathway under study in TNBC is the PI3K/AKT/mTOR 
signaling pathway, with basal-like breast cancers having a high frequency 
of activating PIK3CA mutations and loss of PTEN. Clinical trials are 
underway in the phase II setting with AKT and PI3K inhibitors; however, 
due to the frequency of mutations in many other genes responsible for 
apoptosis, the antitumor effect as monotherapy in TNBC is likely limited. 
It is theorized that PI3K pathway inhibitors many increase DNA damage, 
as well as downregulate BRCA1/2, and therefore further sensitize 
tumor cells to PARPi.13 To evaluate this, a phase 1 trial of the pan-PI3K 
inhibitor BKM120 and olaparib is ongoing (NCT01623349). In addition, AR 
positive TNBCs are more likely to have PIK3CA mutations, and therefore 
antiandrogen plus PI3K inhibitor combinations are also being studied 
(NCT02457910).
Histone deacetylase (HDAC) inhibitors target heat-shock protein 90 (HSP90) 
that chaperones proteins like BRCA1/2. Early studies are evaluating these 
inhibitors in combination with chemotherapy, PARPi, and azacitidine 
(NCT02623751, NCT02393794, NCT01349959). 
Another area of interest has been the growth factor FGFR. Pre-clinical 
work has shown decreased tumor growth with inhibition of FGFR in 
TNBCs with FGFR amplification. Several targeted agents are currently 
in development, and an ongoing trial is evaluating the tyrosine kinase 
inhibitor lucitanib in all breast cancers harboring an FGFR1 or 11q 
amplification (NCT02202746).
Conclusions
TNBC represents a heterogeneous group of breast cancers. Historically, 
a lack of molecular targets has left cytotoxic chemotherapy as the 
only treatment option for controlling systemic disease. However, as 
advancements are made in understanding the biology of TNBC, research is 
underway to understand the role of additional agents, including platinum 
agents, immune checkpoint inhibitors, PARP inhibitors, PI3K pathway 
inhibitors, and others. There is hope that the notoriously poor prognosis 
and limited number of options for TNBC will be transformed in the future by 
a personalized and targeted approach to treatment. q
Table 2: Results of multicenter trial data for the use of  
poly-ADP polymerase inhibitors in BRCA mutated, metastatic 
breast cancer 
Drug Phase Population Notable results
Olaparib58 II Recurrent, advanced BC with 
BRCA1/2 germline mutation 
(n=54)
ORR 41% at dose  
400 mg BID, ORR 22% 
at dose 100 mg BID
Olaparib59 II TNBC or ovarian cancer, 
randomized by BRCA status  
(n=26 with TNBC, n=10 with  
BRCA mutation)
ORR 0% in BC
Olaparib60 II Solid tumors with germline 
BRCA1/2 mutation, BC patients 
with ≥3 lines of prior therapy 
(n=62 with BC)
ORR 12.9%, 47% with 
SD for ≥ 8 weeks in 
patients with BC
Olaparin plus 
cisplatin61
I Metastatic cancer (n=42 with BC, 
16 with BRCA mutated BC)
ORR 71% in BRCA 
mutated BC
Veliparib62 I Solid tumors with germline 
BRCA1/2 mutation or basal-like 
BC (n=14 with BRCA mutated BC)
ORR 29% in BRCA 
mutated BC, CBR 57%
Veliparib plus 
carboplatin63
I Metastatic BC with germline 
BRCA1/2 mutation (n=26, 70%  
of pts ER positive)
ORR 46% (3 CR, 9 PR), 
CBR 74%
Veliparib plus 
carboplain64
I Metastatic BC, TNBC or mutation 
in the Fanconi anemia pathway or 
BRCA1/2 mutation (n=44, 16 with 
BRCA mutation)
25% PR, 62.5% SD in 
BRCA mutated BC
Talazoparib65 I Metastatic solid tumor (n=8 with 
BC, 6 with BRCA mutation)
ORR 33% in BRCA 
mutated BC
Niraparib66 I Metastatic solid tumor (n=12 with 
BC, 4 with BRCA mutation)
ORR 50% in BRCA 
mutated BC
BC = breast cancer; CBR = clinical benefit rate; CR = complete response; ER = estrogen 
receptor; ORR = overall response rate; PR = partial response; SD = stable disease. 
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